引言
造血干细胞移植(hematopoietic cell transplantation, HCT)是很多恶性和非恶性疾病的重要治疗选择，有可能治愈疾病。**移植所需多能造血干细胞(hematopoietic stem cell, HSC)通常来自于亲缘或非亲缘供者的骨髓或外周血。脐带血(umbilical cord blood, UCB)是婴儿出生后留在脐带和胎盘中的血液，已成为同种异体HCT中HSC的明确备选来源。**

本文首先讨论造血作用的HSC模型，之后讨论适用于移植的造血细胞来源。HCT合适供者的选择和潜在供者评估以及脐带血的采集参见其他专题。

●(参见 “造血干细胞移植的供者选择”)

●(参见 “造血干细胞移植的供者评估”)

●(参见 “造血干细胞移植用脐带血的采集和储存”)

●(参见 “造血干细胞移植中脐血移植物的选择”)

术语“HCT”在全文中将作为统称，涵盖任何来源(如骨髓、外周血和脐血)的祖细胞/HSC移植。其他时候会具体说明细胞来源，如自体外周血祖细胞(peripheral blood progenitor cell, PBPC)移植。(参见下文‘造血干细胞的来源’)

干细胞模型

HSC的发现 — 造血是持续终身的过程，由少量的多能HSC从较大的静止池中缓慢进入循环。循环中血细胞是成熟前体细胞的直系后裔，而后者来自于较小的祖细胞池。祖细胞又源自更小的HSC池。HSC是多能的，能够分化成所有谱系的血细胞：红细胞、血小板、中性粒细胞、嗜酸性粒细胞、嗜碱性粒细胞、单核细胞、T淋巴细胞和B淋巴细胞、自然杀伤(natural killer, NK)细胞和树突状细胞(图 1)。

自20世纪50年代的研究开始，人们识别了HSC及其对受到致命性照射动物的保护作用，这些研究发现通过铅屏蔽脾脏或稍后输注正常供者的脾细胞可保护接受放疗的动物。随着体外和体内检测系统的发展(如Till-McCulloch脾集落实验)，能够分化成红系和髓系细胞的克隆性前体细胞得到明确[1]。从功能上HSC定义为能够挽救遭受致死照射动物的细胞群，在概念上这一定义是准确的，但很难适用于不同系统，特别是对于人类。尽管如此，仍可界定为能够实现多系细胞再生并挽救遭受致命照射动物的细胞群。这些HSC可以被再分离和用于挽救其他遭受致命照射的动物。(参见 “造血干细胞的概述”)

随后研发了单克隆抗体，可识别骨髓来源的不成熟和成熟细胞群表面蛋白质。随着细胞分选技术的进步，已有可能分离出有HSC活性的细胞群。通过该方法已分离出高度纯化的鼠骨髓来源HSC群，这种细胞仅需静脉注射100个就能挽救95%以上遭受致命辐射的动物[2]。

人HSC上的标志物 — 尽管确切表型仍有争议，但已用体外和替代体内试验分离出能够多向分化增殖的人类假定性HSC群。**有这些功能的细胞表达HSC抗原CD34且为Lin-；这些细胞也被描述为Thy-1lo、Dr-或CD38-[3,4]**。(参见 “造血干细胞的概述”)

使用高度纯化的CD34+,Thy-1+细胞群的临床试验证实，单用该细胞群就能实现快速和持久的造血植活[5]。此外，在自体HCT后，单是这些细胞就能支持长期造血[6]。纯化HSC在HCT和基因治疗中的临床应用十分广泛。**通过目前的磁珠分离技术，有可能高效分离和纯化CD34+细胞。也有可能进一步提纯CD34+细胞亚群，如使用高速荧光激活细胞分选技术(high speed fluorescence activated cell sorting, FACS)来分离Thy-1+细胞，但以临床规模应用有难度。**

CD34阴性HSC群也有报道[7,8]，其能够使遭受致命性照射的动物获得造血重建[7]。尽管如此，大量临床数据仍支持CD34的表达和所输注的CD34+细胞数与动物及人类中造血重建速度密切相关。(参见下文‘PBPC动员’)

造血干细胞的来源
**数种不同的人类组织中有HSC：骨髓、外周血(尤其是动员后)以及分娩时获得的脐带静脉血。**

骨髓

骨髓采集 — 骨髓采集技术已常规化。一般在区域麻醉或全身麻醉下从后髂嵴抽取骨髓。还可从前髂嵴获得骨髓，但此处可获取量相对有限，一般仅用于诊断性目的。既往接受过骨盆照射的患者不太可能从这些位置采集足够的骨髓，需要使用其他采集方法或其他HSC来源。(参见 “骨髓穿刺与活检的适应证和操作技术”)

**进行多次穿刺，从每个穿刺部位采集约5-10mL的骨髓液，目标为采集至多2x108个细胞/kg受者体重的骨髓液(成人受者需700-1500mL)。美国国家骨髓捐赠计划(National Marrow Donor Program, NMDP)确定的指南规定，采集供者的骨髓液上限为20mL/kg供者体重。骨髓采用肝素或枸橼酸葡萄糖-A抗凝。冷冻保存骨髓前需去除红细胞**。(参见 “造血干细胞移植的供者评估”，关于‘骨髓采集’一节)

经动员的骨髓 — 除了采集未经刺激的骨髓，另一种方法是在**采集前预先使用粒细胞集落刺激因子(granulocyte colony-stimulating factor, G-CSF)，10-16μg/(kg·d)，皮下注射，用3日。一项研究显示，先前接受过多种治疗且外周血干细胞动员不佳的患者，上述方法使其造血功能获得有效恢复[9,10]。一些研究提示，此方法可能降低移植物抗宿主病(graft-versus-host disease, GVHD)的发生率和严重程度。一项较小的随机研究显示，使用G-CSF预处理的骨髓可能带来这些益处[11,12]。然而，这种方法极少用，还需要在较大数量的患者中进行验证[11]**。

细胞数量 — 长期稳定植活所需的细胞数量尚未精准确定，但已确定了一些有参考价值的目标值。一般认为有核细胞数量为2x108/kg是足够的，也使用过低至1x108/kg的细胞数量；但**3项回顾性研究表明，当CD34+细胞数≥3.0x106/kg时造血功能恢复率、移植相关死亡率和5年生存率显著更好[13,14]；而CD34+细胞数<1.2×106/kg时，造血功能恢复率显著更差[15]。按此计算成人受者一般需要700-1500mL的骨髓液，具体取决于受者体重**。(参见下文‘PBPC动员’)

尽管关于细胞数量的研究多着眼于CD34+细胞，但**移植结局可能也受到骨髓移植物内所包含的浆细胞样树突状细胞(plasmacytoid dendritic cell, pDC)数量和初始T细胞数量的影响。例如，对一项前瞻性试验纳入的161例骨髓移植受者的分析显示，pDC数、初始CD8+ T细胞数、恒定NK-T细胞数或初始CD4+ T细胞数高于中位数的受者3年时总体生存率较高(56% vs 35%)[16]。移植物中pDC含量更高与GVHD或排斥所致死亡更少相关。在147例接受PBPC移植的患者中并没有发现这些关联。虽然可调整移植物中特定细胞的含量在临床上很有吸引力，但目前在常规实践中并不评估移植物中T细胞和pDC的数量。**

并发症 — 骨髓采集经常并发轻微的背部或髋部疼痛、疲乏，以及外周血细胞计数一过性变化。骨髓采集的严重并发症极其罕见，包括机械损伤、麻醉并发症、感染和出血，相关内容详见其他专题。(参见 “造血干细胞移植的供者评估”，关于‘并发症’一节)

外周血 — 外周血中可检测到极低水平的HSC[17]。**使用造血生长因子[例如，粒-巨噬细胞集落刺激因子(granulocyte-macrophage colony-stimulating factor, GM-CSF]、G-CSF或使用普乐沙福抑制CXCR4)]或从细胞毒化疗中恢复时，HSC水平可增至1000倍或更多[18-20]。大多数机构使用的采集物混有HSC和祖细胞，称为“外周血祖细胞(PBPC)”，以同研究中仅输注的纯化人HSC相区别**。

**自体HCT中所用的HSC几乎都是PBPC**。异基因干细胞移植中更常用动员后采集的PBPC，但骨髓仍在使用，尤其是对于标危疾病患者或骨髓衰竭综合征(重度再生障碍性贫血)患者。不同HSC来源的疗效对比参见下文。(参见下文‘用于恶性疾病的PBPC VS 骨髓’)

最佳CD34细胞数量 — 现已证实，每千克受者体重的CD34+细胞绝对计数是确定制品的细胞数量是否充足最可靠和最实用的方法。体外造血集落检测与CD34+细胞检测相关；但其实验步骤繁琐并难以标准化，报告结果可能至少需要10日[21,22]。因此，大多数实验室的标准方法是通过FACS测定CD34+细胞含量。目前主要致力于在不同实验室中标准化并验证这一操作过程[23]。许多医疗中心在开始单采之前会检测CD34+细胞含量，以确定PBPC的最佳采集日期。

输注经动员的PBPC后，造血功能迅速重建，中性粒细胞恢复需要约10日，血小板恢复要10-12日。**现已证实CD34+细胞数/kg是有用指标，因为接受>2x106CD34+细胞/kg的患者通常能迅速并持续地恢复造血[24-26]。因此，该数量成为PBPC采集量是否充足的界定标准，采集量达到该值时一般能保证迅速重建造血功能。但目前尚未确定最小细胞数量。许多中心认可的CD34+细胞数是106/kg，但使用这种剂量常可见血小板恢复延迟。**

**“最佳”CD34+细胞数尚不确定，很可能因移植类型而异。自体HCT时，2x106/kg的CD34+细胞似乎足够。而接受HLA全相合同胞供者移植物的患者可能需要更高的CD34+细胞数，即(2-5)x106/kg；接受同种异体非清髓性或单倍体相合移植的患者也可能需要更高的CD34+细胞数，即(10-20)x106/kg。更高剂量(CD34+细胞/kg)可能会使HCT后血小板恢复稍微更快，可能对中性粒细胞恢复有轻微的影响，还可能改善总体生存**[27-42]：

●一项研究显示，对于行自体HCT的非霍奇金淋巴瘤患者，所输注的CD34细胞计数与淋巴细胞绝对计数恢复至≥500/μL的时间呈显著负相关，且输注的CD34细胞计数越多，可获得显著更长的无事件生存期和总生存期[35]。

●一项随机试验比较了G-CSF、GM-CSF及这两种细胞因子联合化疗的动员效果，研究对象为156例乳腺癌、淋巴瘤或多发性骨髓瘤患者[40]。单用G-CSF或G-CSF联合GM-CSF的患者CD34+细胞产量显著更高(每次单采获得CD34+细胞的中位数为7.1x106/kg vs 2.0x106/kg)。CD34+细胞数达到2.5X106/kg的患者比例显著更高(94% vs 78%)。尽管CD34+细胞数越多则植活速度越快，但长期结局无重大差异。

●在另一项研究中，CD34+细胞数>8x106/kg与同种异体移植后发生临床广泛性慢性GVHD的风险增加相关[31]。然而，其他移植研究小组尚未得到此类结果[41]。

CD34+细胞、CD34+亚群、有核细胞总数和其他移植成分的最佳数量需要开展前瞻性研究来证实[43-47]。(参见下文‘T细胞处理’)

PBPC动员 — G-CSF和GM-CSF单用或与化疗或其他刺激剂(例如普乐沙福)联用方案均可用于动员PBPC。G-CSF常用得多。**标准方法是G-CSF单药用于同种异体供者，G-CSF单药或G-CSF+普乐沙福或环磷酰胺用于自体动员。一些中心将普乐沙福仅用于未能动员到足量CD34+细胞的患者，但其他中心更常规地纳入普乐沙福**。(参见 “造血干细胞移植的供者评估”，关于‘操作’一节)

美国临床肿瘤学会发布了使用骨髓生长因子动员PBPC的指南[48]。

G-CSF刺激 — 对于大多数同种异体供者，我们单用G-CSF来动员PBPC。一般给予供者10-16μg/(kg·d)的G-CSF，HSC动员通常发生在第4-5日[24,25,49,50]。多数供者单次采集即可，但为获得≥2x106/kg受者体重的理想CD34+细胞数量，有时可能需要多次采集。(参见上文‘最佳CD34细胞数量’)

动员PBPC的最佳方案尚未明确，已使用了几种不同的方法[51-53]。一项随机研究针对供采集的同种异体移植正常供者，给予10μg/kg、一日1次的G-CSF，或分为5μg/kg、一日2次给药[54]。后一种方案使CD34+细胞产量更高，所需的单采操作次数更少，且不增加毒性或成本。聚乙二醇化重组G-CSF(即培非司亭)是一种长效重组G-CSF，所需给药次数较少，也可成功动员，但不常在成人中用于该目的[55-57]。在另外两项研究中，剂量为20-50μg/(kg·d)的G-CSF提高了CD34+细胞产量，从而减少达到采集目标(>2.5x106或5x106 CD34+细胞/kg)所需的单采天数，但这种方法并未常规使用[58,59]。

G-CSF反应不足 — 大多数患者单用G-CSF可成功动员PBPC，但有些患者难以充分动员[60]。其原因不详，但先前化疗或放疗的程度或基础疾病可能是重要的影响因素[58,61]。(参见上文‘PBPC动员’)

例如，多发性骨髓瘤患者先前使用来那度胺(尤其是超过4-6个月)与G-CSF单药动员后成功采集PBPC的能力降低有关，这可通过使用化疗加G-CSF或加用普乐沙福来解决[62]。尽管有这些结果，但很难在启动动员方案之前预测动员效果较差的患者。

可提高PBPC产量从而减少单采操作次数的策略包括：

●G-CSF联合化疗[19]。(参见下文‘化疗后动员’)

●G-CSF联合CXCR4抑制剂普乐沙福。(参见下文‘普乐沙福’)

●干细胞因子(stem cell factor, SCF；Steel因子、c-kit配体)可用于HSC动员[63]。SCF已在一些国家获批用于此目的，但在美国未获批准。SCF也能激活肥大细胞，产生显著但可控的副作用。尽管单用SCF活性相对有限，但与G-CSF联用会显著增加获得成功动员(即CD34+细胞数≥5x106/kg)的患者百分比[27]。

**普乐沙福 — 对于单用G-CSF或G-CSF+化疗无法动员足量CD34+细胞的患者，我们建议加用普乐沙福。**

普乐沙福抑制基质细胞衍生因子-1(stromal cell-derived factor 1, SDF-1)与其受体CXCR4之间的相互作用，这在PBPC的“运输”中发挥关键作用[51,52]。因此中断这些及其他相互作用可使高功能性的PBPC释放(即动员)入循环中[64-66]。普乐沙福价格昂贵，所以通常仅用于G-CSF或G-CSF+化疗不能动员足量CD34+细胞的患者。在患者接受至少4日的G-CSF后，开始使用普乐沙福。于晚上皮下给予普乐沙福(根据实际体重给予240μg/kg)和G-CSF(10μg/kg)，然后在第2日采集。普乐沙福可每日1次，直至采集到足量细胞，最多连用4日。

以下研究支持应用普乐沙福：

●初始Ⅰ期研究纳入多发性骨髓瘤和非霍奇金淋巴瘤患者，剂量为160μg/kg和240μg/kg。注射后4-6小时，外周血中CD34+细胞快速增加[67]。普乐沙福药物耐受性一般较好，仅有很轻微的副作用。

●对于先前使用化疗或仅用细胞因子动员失败的受试者，G-CSF加普乐沙福可改善CD34+细胞动员[68]，且这一联合方案在动员>5x106CD34+细胞/kg方面优于单用G-CSF，所需单采次数更少[69,70]。

●一项关于298例需要自体HCT的非霍奇金淋巴瘤患者的随机安慰剂对照研究发现，相较于单用G-CSF，普乐沙福加G-CSF组有显著更多的患者可在较少单采天数中实现用于HCT的最佳CD34+细胞目标值[71]。

●一项研究对25例HLA-相合的同胞HCT供者给予普乐沙福(240μg/kg，皮下给予)而不联合G-CSF，并在4小时后开始白细胞单采。单剂普乐沙福后，2/3的供者提供了足够用于移植的CD34+细胞数[72]。没有供者出现1级以上的毒性反应，所有受者均未出现非预期不良事件。在输注动员的细胞后，所有患者都及时实现植活。

美国FDA已批准普乐沙福联合G-CSF用于非霍奇金淋巴瘤和多发性骨髓瘤患者的HSC动员以供采集和随后的自体移植。许多工作组将常规使用普乐沙福的方法仅用于G-CSF或G-CSF+化疗未能动员足量CD34+细胞的患者[73-77]。然而，其他工作组更常规地将其与G-CSF联用。两种策略都有效。(参见 “多发性骨髓瘤的自体造血干细胞移植”，关于‘干细胞的采集’一节)

化疗后动员 — 与单用生长因子相比，在细胞毒化疗恢复后，使用G-CSF+化疗地动员PBPC更有效；化疗后恢复期间循环CD34+细胞>10/μL已用于预测PBPC动员成功[61]。然而，大多数中心首选G-CSF+普乐沙福来动员自体PBPC。(参见上文‘普乐沙福’)

加入G-CSF等生长因子可产生协同作用[78-82]。尽管已开发出可产生这种现象的多种动员方案[80,81,83-87]，但标准方案为环磷酰胺(通常3-4g/m2)联合G-CSF 10μg/kg(四舍五入至最接近的整瓶数)。这一方法已安全且一致地用于多种不同疾病，毒性作用相对较少并可极好地采集CD34+细胞。尽管联合化疗可使恶性肿瘤患者进一步减瘤，但也会导致并发症，如发热性中性粒细胞减少和出血性膀胱炎。因此，化疗联合生长因子只适用于自体移植。

●联用化疗和生长因子后的动员优于单用生长因子–在一项研究中，47例先前接受过多种治疗的复发性或难治性淋巴瘤患者接受联合化疗，敏感性或稳定性疾病患者随机分至单用G-CSF或接受G-CSF+环磷酰胺，随后采集PBPC[81]。初始单用G-CSF治疗的受试者在PBPC采集后接受相同剂量的环磷酰胺；两组随后均接受相同的化疗、受累野放疗和预处理方案，之后输入采集到的PBPC。尽管加用化疗后PBPC动员可采集到更多的CD34+细胞，但两组间中性粒细胞或血小板植活的中位时间、肿瘤细胞污染情况、总生存或无进展生存、资源利用或毒性方面无差异。

●特定情况下G-CSF比GM-CSF更有效–在动员PBPC和化疗动员后减低毒性方面，单用G-CSF或序贯使用GM-CSF和G-CSF均优于单用GM-CSF。为比较这种情况下G-CSF(非格司亭)和GM-CSF(沙格司亭)的作用，158例乳腺癌、淋巴瘤或多发性骨髓瘤患者接受了环磷酰胺加依托泊苷或紫杉醇的化疗[40,88]。之后随机分组，分别单用G-CSF[6μg/(kg·d)]、单用GM-CSF[250μg/(m2·d)]，或持续使用5日GM-CSF后再使用G-CSF，这3种方案从完成化疗后的第2日开始。相较于接受GM-CSF的患者，接受G-CSF的患者有以下特点：

•中性粒细胞绝对计数恢复至≥500/μL的速度更快(11日 vs 14日)

•需要输注红细胞的患者更少

•发热患者更少(18% vs 52%)

•住院患者更少(20% vs 42%)

•使用静脉抗生素治疗的患者更少

•CD34+细胞产量更高(每次单采操作为7.1x106/kg vs 2.0x106/kg)[21-42]

动员效果不佳的危险因素 — 部分患者需要多次单采操作(即4次以上)以获得足够的细胞数。现已尝试预测采集足够细胞数的可能性，以期仅对动员失败可能性更大的个体进行更具侵袭性的动员操作。采集难度增大的预测因素包括循环中CD34+细胞数低、供者年龄较大和总血容量较少。这些因素可用于预测单用G-CSF或G-CSF+化疗的联合方案动员足量PBPC的能力[61,89-100]。

●一项研究显示，对于多发性骨髓瘤和非霍奇金淋巴瘤患者，要确保(概率为95%)成功动员和采集>2.5x106 CD34+细胞/kg所需的外周血最小稳态CD34+细胞浓度分别为1.4/μL和8.9/μL[89]。

●两项涉及多种恶性肿瘤患者的研究发现，单采前CD34+细胞浓度>34/μL或>40/μL时，通过单次常规容量白细胞单采术采集的CD34+细胞数>2.5x106/kg的受试者分别为88%和100%[90,91]。

●一项研究发现，对年龄<18岁(范围1-17)的供者给予G-CSF动员CD34+细胞与≥18岁供者的模式类似，尽管年龄小的供者仅进行一次单采就达到目标细胞数量的比例显著更高(56% vs 39%)[97]。

●一项Ⅱ期研究发现，在进行自体移植PBPC采集的18岁以下儿童中，83%使用单剂聚乙二醇化G-CSF(100μg/kg)获得了足够的动员效果[98]。但成人研究很少，且聚乙二醇化G-CSF不常用于此目的。

●一项连续纳入129例亲缘成人供者的回顾性研究显示，影响循环中CD34+细胞计数(HSC动员的替代标志)的因素包括供者体重和总G-CSF剂量[99]。44例年龄≥55岁的供者与85例<55岁的供者相比，动员效果没有差异。

并发症 — PBPC动员和采集后的并发症发生率很低。供者的潜在风险包括G-CSF相关风险以及单采相关风险。10%-20%的供者发生骨痛，氯雷他定可有效治疗。极少数情况下，使用G-CSF的患者可发生脾肿大并伴脾破裂的风险。根据我们经验，大多数单采可不采用中心静脉通路。相关内容详见其他专题。(参见 “造血干细胞移植的供者评估”，关于‘PBPC捐献的不良反应’一节)

**肿瘤细胞污染 — 动员的PBPC中可能存在肿瘤细胞，但其临床意义不明。一项使用量化PCR技术的研究显示，骨髓和外周血的淋巴瘤细胞负荷差异低于一个log(10倍)[101]。由于未处理PBPC移植物的细胞绝对输注量通常为骨髓移植物的(1-1.5)log倍，所以两种HSC来源最终所输注的肿瘤细胞绝对数量总值可能相近。**

**对于B细胞非霍奇金淋巴瘤患者，动员方案可添加抗-CD20单克隆抗体(monoclonal antibodies, MAbs)以降低采集PBPC被污染的风险。**

脐带血 — 分娩时采集的脐带血(umbilical cord blood, UCB)中HSC含量较高。这些细胞可经过处理并冻存在脐血库中。可通过与识别非亲缘供者的相似方式来搜寻脐血。若配型发现与受者HLA相合，脐带血即以最快的速度从脐血库运送到移植中心使用。(参见 “造血干细胞移植用脐带血的采集和储存”)

**非亲缘UCB作为HSC来源时，比非亲缘供者骨髓或经动员的PBPC有很多实际优势，包括扩大了供者范围、容易获取、无供者流失问题和减少GVHD。**(参见 “造血干细胞移植中脐血移植物的选择”，关于‘脐血移植物的特征’一节)

**UCB的不足包括：移植失败的风险较高，免疫重建延迟，以及无法获得供者的其他捐献(即，供者淋巴细胞输注)**。(参见 “采用清髓性和非清髓性预处理方案进行成人脐带血移植”)

用于恶性疾病的PBPC VS 骨髓

**自体移植 — 几乎所有移植中心都使用PBPC而非骨髓进行自体HCT。在两项研究中，复发淋巴瘤患者被随机分为两组，诱导治疗后分别接受自体PBPC或骨髓移植；结果发现对于植活[102]、支持治疗、生存质量和成本，PBPC均更优[103,104]。然而，两项研究均发现两组的无病生存情况无差异。**

**同种异体移植 — PBPC和骨髓均可作为恶性疾病患者同种异体移植的HSC来源，如何选择必须取决于患者和供者意愿。移植失败或移植后早期感染风险较高的患者可能首选PBPC，因为这种情况下造血恢复较快是其显著优势。与此相符的是，许多移植中心对晚期患者使用经动员的PBPC，而对标危患者使用骨髓移植。**

**PBPC对于同种异体移植的作用得到广泛认可，此时大多在G-CSF动员后采集PBPC[105,106]。大多数患者较易采集到足够数量的CD34+细胞，但同种异体移植最佳的和必需的CD34+细胞数量尚未确定。复发风险较高者(如，晚期疾病)可能首选PBPC，而更接近标危的患者也可接受骨髓。(参见上文‘PBPC动员’)**

一篇包含了9项随机试验、共1521例患者数据的meta分析报道，对于血液系统恶性肿瘤成人患者，干细胞来源(PBPC或骨髓)的选择似乎不会影响总体生存率、无病生存率或非复发性或移植相关的死亡率[107]。PBPC移植的中性粒细胞和血小板植活更快，总体和广泛慢性GVHD发生率更高。

以下研究阐明了这些效应的复杂性：

●一项来自于欧洲血液和骨髓移植合作组(European Cooperative Group for Blood and Marrow Transplantation, EBMT)的大型非随机研究对881例急性髓系白血病(acute myeloid leukemia, AML)成人患者在首次完全缓解时使用高剂量(>2.7x108细胞/kg)或低剂量(<2.7x108细胞/kg)骨髓或PBPC移植，研究了骨髓细胞量的影响[108]。PBPC和低剂量骨髓移植组的治疗相关死亡、无白血病生存和总生存无差异。但高剂量骨髓移植组的治疗相关死亡率显著低于PBPC移植组，无白血病生存和总生存情况也更优。高剂量和低剂量骨髓移植诱发的慢性GVHD均少于PBPC。

●一项针对国际血液和骨髓移植研究中心(Center for International Blood and Marrow Transplant Research, CIBMTR)数据库的回顾性分析中，评估了美国2000-2008年间经减低强度预处理后输注PBPC(887例)或骨髓(219例)的AML、骨髓增生异常综合征(myelodysplastic syndrome, MDS)或非霍奇金淋巴瘤患者的结局[109]，发现干细胞来源似乎不影响移植后5年时的生存率或急、慢性GVHD的发生率。值得关注的是，以甲氨蝶呤+钙调磷酸酶抑制剂预防GVHD的患者的生存率高于以吗替麦考酚酯+钙调磷酸酶抑制剂进行预防治疗的患者，但该结果还需进一步研究。(参见 “移植物抗宿主病的预防”)

●一项随机试验纳入350例急性白血病首次缓解期或慢性髓系白血病(chronic myeloid leukemia, CML)首个慢性期的患者，证实了使用PBPC可导致血小板和中性粒细胞更快速恢复，这与所有既往研究一致[110]。PBPC组有显著更高的Ⅱ-Ⅳ级急性GVHD发生率(52% vs 39%，OR 1.74，95%CI 1.1-2.7)和慢性GVHD发生率(67% vs 54%，OR 1.7，95%CI 1.2-2.4)。无论HSC来源如何，2年时的估计生存率均为65%。

●在另一项随机试验中，228例<65岁的CML、AML或MDS患者被分配接受HLA-相合同胞的非格司亭动员PBPC或骨髓[111]。PBPC移植组血小板计数恢复至>20,000/μL的时间和中性粒细胞绝对计数恢复至>500/μL的时间显著更短，分别比骨髓移植少6日和4日。两组患者Ⅱ-Ⅳ级急性GVHD的发生率相等(44%)，广泛的慢性GVHD发生率相近。而移植后30个月时，PBPC移植受者的总体生存率显著更高(68% vs 60%，HR 0.62，95%CI 0.39-0.97)。

●一项Ⅲ期试验纳入551例接受HLA相合非亲缘供者同种异体HCT的成人患者，随机分至接受经非格司亭动员的PBPC或骨髓[112]。中位随访时间36个月时，PBPC组患者中位血小板计数恢复时间和中性粒细胞计数恢复时间显著更短(分别少7日和5日)、移植失败的发生率更低(3% vs 9%)而急性GVHD发生率相近，但广泛慢性GVHD发生率增加(48% vs 32%)，到2年时未接受GVHD治疗的患者比例更低(37% vs 57%)，而2年总生存率相近(51% vs 46%)。

**尚无有力证据表明PBPC用于成人同种异体HCT优于骨髓，但2项回顾性研究发现，在急性白血病[113]或重型再生障碍性贫血的儿童和青少年患者中PBPC不及骨髓[114]。虽然大多数研究和一项meta分析的结论认为，PBPC移植后造血重建和早期免疫血液学重建显著更快[115-117]，不过在PBPC移植后急性和慢性(广泛性)GVHD可能更常见[117-122]，但可能产生有益的移植物抗肿瘤效应和/或改善长期结局**[111,117,122-124]。

一项对329例接受HCT的白血病患者随访9年的随机试验显示，PBPC组和骨髓组的总体和无白血病生存率相近[119]。尽管慢性GVHD的发生率和免疫抑制持续时间存在显著差异，但生存情况、一般健康情况及晚期事件的发生率未受不良影响。

T细胞处理
大多数研究主要关注人类HSC和祖细胞的动员。然而，常规的CD4+和CD8+ T细胞(包括不同亚群，如初始和记忆T细胞)、NK细胞、恒定NK-T细胞和调节性T细胞(regulatory T cells, Tregs)等细胞群可能也有临床意义，如在同种异体移植中调节移植物抗肿瘤效应、GVHD风险和/或移植物排斥反应的风险[36,37,125-128]。(参见 “移植物抗宿主病的预防”和 “免疫治疗在预防和治疗异基因造血干细胞移植后复发中的应用”，关于‘供者淋巴细胞输注’一节和 “异基因造血干细胞移植后免疫重建策略”，关于‘移植物处理和干细胞剂量’一节)

**GVHD主要是一种T细胞介导的疾病。因此，输注骨髓前将T细胞从供者移植物中去除是降低GVHD发生率备受关注的方法。早期研究显示，去除T细胞后GVHD发生率降低，但移植失败、免疫重建延迟、疾病复发和发生移植后淋巴增殖性疾病的情况增多；因此，无病生存情况并无总体显著改善。后续研究获得了更有利的结果，即GVHD风险降低且总体生存极佳[129,130]**。一项多中心、三臂随机试验评估了CD34+细胞选择法去除T细胞。相关内容详见其他专题。(参见 “移植物抗宿主病的预防”，关于‘体内TCD’一节)

但几项小型研究却证实，**移植物中Tregs和/或恒定NK-T细胞数较高与免疫重建更佳和GVHD和巨细胞病毒感染减少相关**。(参见 “移植物抗宿主病的发病机制”，关于‘病理生理学’一节和 “异基因造血干细胞移植后免疫重建策略”，关于‘移植物处理和干细胞剂量’一节)

干细胞的输注
骨髓或PBPC输注过程相对简单，在床旁进行。同种异体移植中，骨髓移植一般使用新鲜骨髓，通过中央静脉持续输注数小时。自体移植物制品几乎都是事先冻存的[131]。在床旁解冻后，以数分钟时间快速输注。

HSC“归巢”到骨髓腔内的机制尚未完全阐明[132]，血管细胞黏附分子-1(vascular cell adhesion molecule-1, VCAM-1)、硫酸肝素、SDF-1及其受体(CXCR4)可能参与其中[133-136]。(参见上文‘普乐沙福’)

副作用 — 大多数病例出现了轻微毒性作用。骨髓输注时偶有发热，但大多数患者对于这种输注的耐受能力类似于输血。输注ABO血型不合的骨髓可发生溶血反应，可通过补液和给予利尿剂的标准方式治疗。

输注冷冻保存的外周血干细胞时，发热、咳嗽、恶心、呕吐、潮红、头痛和(偶尔)支气管痉挛等轻微毒性反应相对常见且呈自限性，可能与单采制品中的粒细胞或非单个核细胞的数量有关[137,138]，冷冻保护剂DMSO也可能是促成因素。大多数反应在输注完成后很快消失。保护剂DMSO会在1-2日内发出特殊气味。低血压、心律失常和电解质紊乱等显著输注毒性反应极少见[139]。

可通过筛选HSC群(如CD34+细胞)来降低发生输注毒性反应的风险[139]。主要和次要ABO不相容可引起急性溶血性输血反应；对于ABO主要不相容的患者，需去除输注物中的红细胞[140]。输注PBPC时如果存在ABO主要不相容也可去除血浆，但我们不常规使用该方法，而是通过补充足量水分来避免轻度输血反应和溶血等并发症。

患者教育
UpToDate提供两种类型的患者教育资料：“基础篇”和“高级篇”。基础篇通俗易懂，相当于5-6年级阅读水平(美国)，可以解答关于某种疾病患者可能想了解的4-5个关键问题；基础篇更适合想了解疾病概况且喜欢阅读简短易读资料的患者。高级篇篇幅较长，内容更深入详尽；相当于10-12年级阅读水平(美国)，适合想深入了解并且能接受一些医学术语的患者。

以下是与此专题相关的患者教育资料。我们建议您以打印或电子邮件的方式给予患者。(您也可以通过检索“患者教育”和关键词找到更多相关专题内容。)

●高级篇(参见 “Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)”)

总结

●造血干细胞(HSC)生物学的迅速发展显著增进了我们对移植生物学基础的理解。随着外周血祖细胞(PBPC)和脐带血(UCB)的出现，HSC有了其他来源。HSC制品的最佳来源和组成仍是目前的临床研究热点。

●自体移植时，多数移植小组对大多数病例使用PBPC。最佳的HSC剂量可通过CD34+细胞数来计算。例如，采用针对移植制品的荧光激活细胞分选(FACS)分析确定CD34+细胞的百分比，再以有核细胞总计数确定采集的总细胞数，然后将总细胞数与CD34+细胞的百分比相乘。这样可计算出CD34+细胞总数，然后除以受者体重得到每千克体重CD34+细胞数。一般应用的剂量为>2×106/kg受者体重。(参见上文‘PBPC动员’)

●同种异体移植时，情况复杂得多。骨髓或PBPC移植哪个最佳尚无定论。PBPC植活快于骨髓，但T细胞负荷高可能增加移植物抗宿主病(GVHD)发生率，尤其是慢性GVHD。对于恶性疾病治疗，许多移植中心对晚期患者使用经动员的PBPC，而对标危患者使用骨髓。(参见上文‘用于恶性疾病的PBPC VS 骨髓’)

●非亲缘供者细胞、脐血及单倍体相合供者的相对优势仍有待确定，不同移植中心的选择各异。不过这些供者来源似乎都可接受，这提高了有需求的患者找到供者的可能性。(参见 “造血干细胞移植的供者选择”)

参考文献

1.  [Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol 1995; 11:35.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/1)
2.  [Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. Science 1988; 241:58.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/2)
3.  [Baum CM, Weissman IL, Tsukamoto AS, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A 1992; 89:2804.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/3)
4.  [Craig W, Kay R, Cutler RL, Lansdorp PM. Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 1993; 177:1331.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/4)
5.  [Negrin RS, Atkinson K, Leemhuis T, et al. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant 2000; 6:262.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/5)
6.  [Müller AM, Kohrt HE, Cha S, et al. Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells. Biol Blood Marrow Transplant 2012; 18:125.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/6)
7.  [Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997; 3:1337.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/7)
8.  [Nakauchi H. Hematopoietic stem cells: are they CD34-positive or CD34-negative? Nat Med 1998; 4:1009.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/8)
9.  [Lemoli RM, de Vivo A, Damiani D, et al. Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilization. Blood 2003; 102:1595.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/9)
10.  [Seshadri T, Al-Farsi K, Stakiw J, et al. G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation. Bone Marrow Transplant 2008; 42:733.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/10)
11.  [Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98:3186.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/11)
12.  [Ostronoff M, Ostronoff F, Souto Maior P, et al. Pilot study of allogeneic G-CSF-stimulated bone marrow transplantation: harvest, engraftment, and graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12:729.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/12)
13.  [Bahçeci E, Read EJ, Leitman S, et al. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies. Br J Haematol 2000; 108:408.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/13)
14.  [Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99:2726.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/14)
15.  [Zubair AC, Zahrieh D, Daley H, et al. Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion 2004; 44:253.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/15)
16.  [Waller EK, Logan BR, Harris WA, et al. Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. J Clin Oncol 2014; 32:2365.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/16)
17.  [McCredie KB, Hersh EM, Freireich EJ. Cells capable of colony formation in the peripheral blood of man. Science 1971; 171:293.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/17)
18.  [Siena S, Bregni M, Brando B, et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74:1905.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/18)
19.  [Socinski MA, Cannistra SA, Elias A, et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1:1194.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/19)
20.  [Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339:640.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/20)
21.  [Van Hennik PB, Breems DA, Kusadasi N, et al. Stroma-supported progenitor production as a prognostic tool for graft failure following autologous stem cell transplantation. Br J Haematol 2000; 111:674.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/21)
22.  [Jansen EM, Hanks SG, Terry C, et al. Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both? Transfusion 2007; 47:817.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/22)
23.  [Dzik W, Sniecinski I, Fischer J. Toward standardization of CD34+ cell enumeration: an international study. Biomedial Excellence for Safer Transfusion Working Party. Transfusion 1999; 39:856.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/23)
24.  [Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85:588.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/24)
25.  [Bensinger WI, Longin K, Appelbaum F, et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87:825.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/25)
26.  [Negrin RS, Kusnierz-Glaz CR, Still BJ, et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995; 85:3334.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/26)
27.  [Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997; 90:2939.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/27)
28.  [Ketterer N, Salles G, Raba M, et al. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91:3148.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/28)
29.  [Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86:3961.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/29)
30.  [Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18:1360.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/30)
31.  [Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98:3221.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/31)
32.  [Singh AK, Savani BN, Albert PS, Barrett AJ. Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant 2007; 13:339.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/32)
33.  [Robin M, Kernèis S, Porcher R, et al. Influence of bone marrow nucleated red blood cell dose on outcome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2008; 140:725.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/33)
34.  [Pulsipher MA, Chitphakdithai P, Logan BR, et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009; 114:2606.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/34)
35.  [Yoon DH, Sohn BS, Jang G, et al. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion 2009; 49:1890.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/35)
36.  [Urbano-Ispizua A, Carreras E, Marín P, et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells? Blood 2001; 98:2352.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/36)
37.  [Nakamura R, Bahceci E, Read EJ, et al. Transplant dose of CD34(+) and CD3(+) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. Br J Haematol 2001; 115:95.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/37)
38.  [Urbano-Ispizua A, Rozman C, Pimentel P, et al. Risk factors for acute graft-versus-host disease in patients undergoing transplantation with CD34+ selected blood cells from HLA-identical siblings. Blood 2002; 100:724.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/38)
39.  [Mehta J, Mehta J, Frankfurt O, et al. Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2009; 50:1434.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/39)
40.  [Weaver CH, Schulman KA, Wilson-Relyea B, et al. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000; 18:43.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/40)
41.  [Cao TM, Wong RM, Sheehan K, et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol 2005; 33:279.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/41)
42.  [Ringdén O, Barrett AJ, Zhang MJ, et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 2003; 121:874.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/42)
43.  [Duggan PR, Guo D, Luider J, et al. Predictive factors for long-term engraftment of autologous blood stem cells. Bone Marrow Transplant 2000; 26:1299.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/43)
44.  [Sumikuma T, Shimazaki C, Inaba T, et al. CD34+/CD90+ cells infused best predict late haematopoietic reconstitution following autologous peripheral blood stem cell transplantation. Br J Haematol 2002; 117:238.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/44)
45.  [Kozuka T, Ikeda K, Teshima T, et al. Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization. Transfusion 2002; 42:1514.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/45)
46.  [Perez-Simon JA, Diez-Campelo M, Martino R, et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003; 102:1108.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/46)
47.  [Dominietto A, Lamparelli T, Raiola AM, et al. Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. Blood 2002; 100:3930.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/47)
48.  [Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33:3199.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/48)
49.  [Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81:2031.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/49)
50.  [de Fabritiis P, Iori AP, Mengarelli A, et al. CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. Transfusion 2001; 41:190.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/50)
51.  [Fruehauf S, Seggewiss R. It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected]. Br J Haematol 2003; 122:360.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/51)
52.  [Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood 2004; 103:1580.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/52)
53.  [Gertz MA. Current status of stem cell mobilization. Br J Haematol 2010; 150:647.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/53)
54.  [Kröger N, Renges H, Krüger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111:761.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/54)
55.  [Kroschinsky F, Hölig K, Poppe-Thiede K, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005; 90:1665.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/55)
56.  [Isidori A, Tani M, Bonifazi F, et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90:225.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/56)
57.  [Simona B, Cristina R, Luca N, et al. A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. Transfus Apher Sci 2010; 43:321.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/57)
58.  [Koenigsmann M, Jentsch-Ullrich K, Mohren M, et al. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004; 44:777.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/58)
59.  [Weaver CH, Birch R, Greco FA, et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100:338.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/59)
60.  [To LB, Levesque JP, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011; 118:4530.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/60)
61.  [Visani G, Lemoli RM, Tosi P, et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105:775.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/61)
62.  [Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15:718.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/62)
63.  [Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91:1101.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/63)
64.  [Pelus LM, Fukuda S. Chemokine-mobilized adult stem cells; defining a better hematopoietic graft. Leukemia 2008; 22:466.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/64)
65.  [Ramirez P, Rettig MP, Uy GL, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009; 114:1340.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/65)
66.  [Vose JM, Ho AD, Coiffier B, et al. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009; 50:1412.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/66)
67.  [Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:1095.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/67)
68.  [Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41:331.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/68)
69.  [Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106:1867.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/69)
70.  [DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113:5720.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/70)
71.  [DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27:4767.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/71)
72.  [Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112:990.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/72)
73.  [Giralt S, Stadtmauer EA, Harousseau JL, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23:1904.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/73)
74.  [Tricot G, Cottler-Fox MH, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization. Bone Marrow Transplant 2010; 45:63.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/74)
75.  [Worel N, Rosskopf K, Neumeister P, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 2011; 51:968.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/75)
76.  [Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012; 52:55.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/76)
77.  [Bilgin YM, Visser O, Beckers EA, et al. Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor. Transfusion 2015; 55:1021.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/77)
78.  [Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13:2547.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/78)
79.  [Copelan EA, Ceselski SK, Ezzone SA, et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997; 15:759.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/79)
80.  [Koç ON, Gerson SL, Cooper BW, et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18:1824.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/80)
81.  [Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98:2059.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/81)
82.  [Ameen RM, Alshemmari SH, Alqallaf D. Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies. Clin Lymphoma Myeloma 2008; 8:106.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/82)
83.  [Schwella N, Braun A, Ahrens N, et al. Leukapheresis after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: a novel approach to harvest a second autograft. Transfusion 2003; 43:259.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/83)
84.  [Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000; 95:1588.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/84)
85.  [Hicks ML, Lonial S, Langston A, et al. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion 2007; 47:629.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/85)
86.  [Bruns I, Steidl U, Kronenwett R, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006; 46:180.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/86)
87.  [Kroschinsky F, Hölig K, Platzbecker U, et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 2006; 46:1417.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/87)
88.  [Weaver CH, Schulman KA, Buckner CD. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant 2001; 27 Suppl 2:S23.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/88)
89.  [Fruehauf S, Schmitt K, Veldwijk MR, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 1999; 105:786.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/89)
90.  [Heuft HG, Dubiel M, Rick O, et al. Inverse relationship between patient peripheral blood CD34+ cell counts and collection efficiency for CD34+ cells in two automated leukapheresis systems. Transfusion 2001; 41:1008.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/90)
91.  [Demirer T, Ilhan O, Ayli M, et al. Monitoring of peripheral blood CD34+ cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield. Ther Apher 2002; 6:384.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/91)
92.  [Moncada V, Bolan C, Yau YY, Leitman SF. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. Transfusion 2003; 43:495.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/92)
93.  [Szwajcer D, Jennings-Coutts A, Giftakis A, Wall DA. Identification of the CD34 enumeration on the day before stem cell harvest that best predicts poor mobilization. Transfusion 2011; 51:587.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/93)
94.  [Humpe A, Riggert J, Meineke I, et al. A cell-kinetic model of CD34+ cell mobilization and harvest: development of a predictive algorithm for CD34+ cell yield in PBPC collections. Transfusion 2000; 40:1363.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/94)
95.  [Anderlini P, Przepiorka D, Lauppe J, et al. Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol 1997; 97:485.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/95)
96.  [Tricot G, Morris CL, Siegel E, et al. Peripheral blood stem cell mobilization in elderly (≥70 years) versus younger patients: A study of 984 multiple myeloma patients [abstract]. Proc ASCO 2002; 21:264a.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/96)
97.  [de La Rubia J, Díaz MA, Verdeguer A, et al. Donor age-related differences in PBPC mobilization with rHuG-CSF. Transfusion 2001; 41:201.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/97)
98.  [Cesaro S, Zanazzo AG, Frenos S, et al. A Phase II study on the safety and efficacy of a single dose of pegfilgrastim for mobilization and transplantation of autologous hematopoietic stem cells in pediatric oncohematology patients. Transfusion 2011; 51:2480.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/98)
99.  [de Lavallade H, Ladaique P, Lemarié C, et al. Older age does not influence allogeneic peripheral blood stem cell mobilization in a donor population of mostly white ethnic origin. Blood 2009; 113:1868.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/99)
100.  [Lefrère F, Zohar S, Beaudier S, et al. Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis. Transfusion 2007; 47:1851.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/100)
101.  [Léonard BM, Hétu F, Busque L, et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 1998; 91:331.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/101)
102.  [Ottinger HD, Beelen DW, Scheulen B, et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88:2775.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/102)
103.  [Vellenga E, van Agthoven M, Croockewit AJ, et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol 2001; 114:319.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/103)
104.  [Vose JM, Sharp G, Chan WC, et al. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J Clin Oncol 2002; 20:2344.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/104)
105.  [Tjønnfjord GE, Steen R, Evensen SA, et al. Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994; 84:2795.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/105)
106.  [Anderlini P, Körbling M, Dale D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90:903.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/106)
107.  [Holtick U, Albrecht M, Chemnitz JM, et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev 2014; :CD010189.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/107)
108.  [Gorin NC, Labopin M, Rocha V, et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood 2003; 102:3043.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/108)
109.  [Eapen M, Logan BR, Horowitz MM, et al. Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J Clin Oncol 2015; 33:364.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/109)
110.  [Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100:761.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/110)
111.  [Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100:1525.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/111)
112.  [Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367:1487.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/112)
113.  [Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22:4872.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/113)
114.  [Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood 2007; 110:1397.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/114)
115.  [Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97:3380.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/115)
116.  [Lapierre V, Oubouzar N, Aupérin A, et al. Influence of the hematopoietic stem cell source on early immunohematologic reconstitution after allogeneic transplantation. Blood 2001; 97:2580.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/116)
117.  [Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23:5074.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/117)
118.  [Schmitz N, Eapen M, Horowitz MM, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006; 108:4288.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/118)
119.  [Friedrichs B, Tichelli A, Bacigalupo A, et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010; 11:331.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/119)
120.  [Storek J, Gooley T, Siadak M, et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90:4705.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/120)
121.  [Remberger M, Beelen DW, Fauser A, et al. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105:548.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/121)
122.  [Dey BR, Shaffer J, Yee AJ, et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant 2007; 40:19.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/122)
123.  [Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344:175.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/123)
124.  [Brunet S, Urbano-Ispizua A, Ojeda E, et al. Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. Br J Haematol 2001; 114:544.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/124)
125.  [Bornhäuser M, Platzbecker U, Theuser C, et al. CD34+-enriched peripheral blood progenitor cells from unrelated donors for allografting of adult patients: high risk of graft failure, infection and relapse despite donor lymphocyte add-back. Br J Haematol 2002; 118:1095.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/125)
126.  [Panse JP, Heimfeld S, Guthrie KA, et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol 2005; 128:659.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/126)
127.  [Cao TM, Shizuru JA, Wong RM, et al. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood 2005; 105:2300.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/127)
128.  [Larghero J, Rocha V, Porcher R, et al. Association of bone marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after HLA identical sibling bone marrow transplants. Br J Haematol 2007; 138:101.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/128)
129.  [Devine SM, Carter S, Soiffer RJ, et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant 2011; 17:1343.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/129)
130.  [Jakubowski AA, Small TN, Young JW, et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood 2007; 110:4552.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/130)
131.  [Berz D, McCormack EM, Winer ES, et al. Cryopreservation of hematopoietic stem cells. Am J Hematol 2007; 82:463.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/131)
132.  [Tavassoli M, Hardy CL. Molecular basis of homing of intravenously transplanted stem cells to the marrow. Blood 1990; 76:1059.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/132)
133.  [Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999; 283:845.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/133)
134.  [Simmons PJ, Masinovsky B, Longenecker BM, et al. Vascular cell adhesion molecule-1 expressed by bone marrow stromal cells mediates the binding of hematopoietic progenitor cells. Blood 1992; 80:388.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/134)
135.  [Siczkowski M, Clarke D, Gordon MY. Binding of primitive hematopoietic progenitor cells to marrow stromal cells involves heparan sulfate. Blood 1992; 80:912.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/135)
136.  [Papayannopoulou T, Priestley GV, Nakamoto B, et al. Molecular pathways in bone marrow homing: dominant role of alpha(4)beta(1) over beta(2)-integrins and selectins. Blood 2001; 98:2403.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/136)
137.  [Calmels B, Lemarié C, Esterni B, et al. Occurrence and severity of adverse events after autologous hematopoietic progenitor cell infusion are related to the amount of granulocytes in the apheresis product. Transfusion 2007; 47:1268.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/137)
138.  [Milone G, Pinto V, Mercurio S, et al. Adverse events after infusions of cryopreserved hematopoietic stem cells depend on non-mononuclear cell in infused suspention and on patient age (abstract). Blood 2006; 108:402b.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/138)
139.  [Shpall EJ, LeMaistre CF, Holland K, et al. A prospective randomized trial of buffy coat versus CD34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood 1997; 90:4313.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/139)
140.  [Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 1988; 45:530.](https://www.uptodate.cn/contents/zh-Hans/sources-of-hematopoietic-stem-cells/abstract/140)